文献速递临床试验与 GCP基础与转化研究

高流量发光二极管红光对白种非西班牙裔皮肤的单盲剂量递增I期研究:随机对照试验研究方案

A single-blind, dose-escalation, phase I study of high-fluence light-emitting diode-red light on Caucasian non-Hispanic skin: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-03-20

该研究为单盲、剂量递增、随机对照的I期试验(STARS 2),在健康白种非西班牙裔个体中评估高流量发光二极管红光(HF-LED-RL)480 J/cm2和640 J/cm2的安全性。受试者按3:2随机分配至HF-LED-RL或模拟治疗组,每组5人,从480 J/cm2开始递增至640 J/cm2,确定最大耐受剂量(MTD)。每个受试者接受共9次照射,每周3次连续3周。

要点

  • HF-LED-RL在有色人种皮肤中已确定MTD为320 J/cm2,本研究探索白种非西班牙裔皮肤480和640 J/cm2的安全性。
  • 采用单盲、随机、剂量递增设计,受试者按3:2随机分配至HF-LED-RL或模拟治疗,每组5人。
  • MTD定义为低于2例及以上受试者(>20%队列)出现剂量限制性毒性(DLT)的剂量水平。

核心结论

  • 该研究旨在为HF-LED-RL光疗在480和640 J/cm2剂量下的安全性和皮肤效应提供重要知识,并可能基于种族和民族建立新的治疗范式和安全性特征。

研究设计与样本

  • 单盲、剂量递增、随机对照I期试验(STARS 2),在健康白种非西班牙裔个体中进行。
  • 受试者按3:2随机分配至HF-LED-RL光疗组或模拟治疗组,每组5人。
  • 第1组接受480 J/cm2起始剂量,第2组递增至640 J/cm2。
  • 在确定MTD或达到640 J/cm2研究终点后,额外入组HF-LED-RL和模拟治疗受试者(第3组),总样本量最多60例。
  • 每个受试者接受共9次照射,每周3次连续3周。

主要发现

  • 此前已确定HF-LED-RL在有色人种皮肤中的MTD为320 J/cm2。
  • 据我们所知,尚无临床试验确定更高剂量HF-LED-RL在白种非西班牙裔个体中的安全性。

关键数值与推荐

  • MTD定义为低于2例及以上受试者(>20%队列)出现DLT的剂量水平。
  • 第1组起始剂量为480 J/cm2,第2组递增至640 J/cm2。
  • 总样本量最多60例,每组5人(3例HF-LED-RL,2例模拟治疗)。
  • 每个受试者接受9次照射,每周3次连续3周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Visible light (400 to 700 nm) is common in our environment, comprising 44% of total solar radiation and a large component of environmental light exposure. The effects of visible light on skin remain undefined. The red light portion of the visible spectrum (600 to 700 nm) may be used to treat skin diseases as a monotherapeutic modality or in combination with other agents. Light-emitting diode-red light (LED-RL) phototherapy may represent an important advance in light-based treatment modalities because it is non-invasive, inexpensive, portable, and easily combinable with other therapies. We previously determined the maximum tolerated dose (MTD) of high-fluence LED-RL (HF-LED-RL) in skin of color individuals to be 320 J/cm2. To the best of our knowledge, no clinical trials have been performed to determine the safety of higher doses of HF-LED-RL in Caucasian non-Hispanic individuals. The aim of this study is to investigate the safety of HF-LED-RL at doses of 480 and 640 J/cm2 in healthy Caucasian non-Hispanic individuals. METHODS: This is a single-blind, dose-escalation, randomized, controlled, phase I trial titled Safety Trial Assessing Red-light on Skin (STARS) 2. Healthy subjects will be randomly assigned to groups of five (three subjects randomly assigned to HF-LED-RL phototherapy and two subjects randomly assigned to mock therapy). Subjects in group 1 will receive HF-LED-RL or mock irradiation at the starting dose of 480 J/cm2, and the dose will be escalated in the subsequent group (group 2) to 640 J/cm2. The MTD is defined as the dose level below the dose at which two or more subjects (>20% of the cohort) experience a dose-limiting toxicity (DLT). After either the MTD is established or the study endpoint of 640 J/cm2 is achieved, additional HF-LED-RL phototherapy subjects and mock therapy subjects will be enrolled at that fluence (group 3) for a total number of up to 60 subjects. Each subject will receive a total of nine irradiation sessions, three times per week for three consecutive weeks. DISCUSSION: This follow-up study aims to provide important knowledge about safety and cutaneous effects of HF-LED-RL phototherapy of 480 and 640 J/cm2 in Caucasian non-Hispanic subjects. The importance of this clinical trial is that it may establish new treatment paradigms and a safety profile for LED-RL based on race and ethnicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03433222 . Registered on February 1, 2018 - Retrospectively registered. Protocol date and version: January 12, 2018; version 1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang EB, Kaur R, Nguyen J, et al. A single-blind, dose-escalation, phase I study of high-fluence light-emitting diode-red light on Caucasian non-Hispanic skin: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30894210. doi:10.1186/s13063-019-3278-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。